US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma

Vandana Singh
Updated 1 min read
1
In this article:

  • A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ: ABUS) patent related to a legal fight over Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines.

  • The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.

  • Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, Reuters reported, and the board invalidated it in 2019.

  • The Federal Circuit's decision does not affect an ongoing lawsuit Arbutus and Genevant Sciences filed against Moderna last year in Delaware for allegedly infringing other related LNP patents.

  • Last year in February, Arbutus and Genevant sued Moderna for infringing on their patent on a lipid nanoparticle platform that they say was crucial to delivering Moderna's widely-used COVID-19 vaccine.

  • The companies seek compensation.

  • Arbutus separately sued Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for patent infringement of five US patents last week over their COVID-19 shots.

  • Price Action: ABUS shares are down 1.03% at $2.88, and MRNA shares are up 0.30% at $155.72 on the last check Wednesday.

  • Image by Okan Caliskan from Pixabay

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories